A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
作者
J. Nehra,Penelope Anne Bradbury,Peter Ellis,Janessa J. Laskin,Christian Kollmannsberger,Desirée Hao,Rosalyn Anne Juergens,G. D. Goss,Paul Wheatley‐Price,Sebastién J. Hotte,Karen A. Gelmon,A. V. Tinker,Pamela Brown-Walker,L. Gauthier,Dongsheng Tu,Xuyang Song,Adeel M. Khan,Lesley Seymour,Martin Smoragiewicz